Bladder Cancer
Prostate Cancer
EAU Edu Platform on Kidney Cancer
Home
Articles
Article of the Month
Editorials
Videos
Webcasts
Education
E-courses
Webinars
Online curriculum
Guidelines
Events
Home
Articles
Terug
Article of the Month
Editorials
Videos
Webcasts
Education
Terug
E-courses
Webinars
Online curriculum
Guidelines
Events
Upcoming event
17th European Multidisciplinary Congress on Urological Cancers
Home
/
ESMO25
Back
Tag:
ESMO25
Neoadjuvant immunotherapy in locally advanced clear cell renal cell carcinoma at risk for recurrence or distant metastases: The randomized phase II NESCIO trial
View
LenCabo: A randomized phase II multicenter trial of lenvatinib plus everolimus (len/eve) versus (vs) cabozantinib (cabo) in patients (pts) with metastatic clear cell RCC (ccRCC) that progressed on PD-1 immune checkpoint inhibition (ICI)
View
First results from RAMPART: An international phase III randomised-controlled trial of adjuvant durvalumab monotherapy or combined with tremelimumab for resected primary renal cell carcinoma (RCC) led by MRC CTU at UCL
View
This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
I agree
Read More